ISPOR-FDA Summit 2020 on Patient-Preference Information in Medical Devices Is Now Virtual

Published Jun 22, 2020

September 29 Summit Offers Complimentary Registration for All

ISPOR-FDA Summit 2020Lawrenceville, NJ, USA—June 22, 2020—ISPOR—the professional society for health economics and outcomes research, announced that its joint ISPOR-FDA Summit 2020 has been redesigned as a completely virtual event. The Summit, “Using Patient-Preference Information in Medical Device Regulatory Decisions: Benefit-Risk and Beyond,” is jointly sponsored by ISPOR and the US Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH). The virtual event will be held on September 29, 2020. Registration is being offered free of charge for all attendees.

Patient-preference information is increasingly being used in regulatory decision making for medical devices. Virtual ISPOR-FDA Summit 2020 will provide a forum to engage key stakeholders, including patient representatives, the medical device industry, researchers, payers and policymakers, healthcare providers, assessors, and regulators to discuss and explore the role, challenges, and opportunities of using patient-preference information across the healthcare ecosystem.

Summit speakers currently confirmed include: Michelle Tarver, MD, PhD, Center for Devices and Radiological Health, FDA; Anindita Saha, MS, Center for Devices and Radiological Health, FDA; David Gebben, PhD, Center for Devices and Radiological Health, FDA; Ryan Fischer, Parent Project Muscular Dystrophy; Suzanne Schrandt, JD, ExPPect, LLC; Juan Marcos Gonzalez, PhD, Duke University School of Medicine; Brett Hauber, PhD, RTI Health Solutions; Shelby Reed, RPh, PhD, Duke Clinical Research Institute; Ravishankar Jayadevappa, PhD, University of Pennsylvania Perelman School of Medicine; Dean Bruhn-Ding, RAC, CVRx, Inc; Dan Harfe, Tusker Medical, Inc; Bennett Levitan, MD, PhD, Janssen Research and Development; Barry R. Liden, Edwards Lifesciences; and Todd Snell, NxStage Medical of Fresenius Medical Care North America.

Registration for the Summit is complimentary. Prior registrants (for the previously scheduled event on March 31) do need to re-register for the new, completely virtual event now scheduled for September 29.

A pre-event webinar, “Patient-Preference Information—What It Is and What It Is Not,” is currently available on demand and provides a primer on the topic of patient-preference information. The webinar is recommended for Summit participants, is complimentary, and is available to be viewed by all (both registrants and non-registrants).

Additional information on Virtual ISPOR-FDA Summit 2020 can be found at:
Virtual ISPOR-FDA Summit 2020  |  Summit Program  |  Registration Information   |  Press

###

 

ABOUT ISPOR
ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Website  | LinkedIn  | Twitter (@ispororg)  |  YouTube  |  Facebook  |  Instagram

Explore Related HEOR by Topic


Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×